Dialysis adequacy today: A European perspective

Nephrology Dialysis Transplantation

Volumn 27, Issue 8, 2012, Pages 3043-3048

  Locatelli, Francesco ^a   Canaud, Bernard ^b  

^a A MANZONI HOSPITAL   (Italy)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

convective treatments; efficacy; haemodialysis; medical care; quality

Indexed keywords

UREMIC TOXIN;

CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; DIALYSIS MEMBRANE; DISEASE ASSOCIATION; FLUID BALANCE; FLUID TRANSPORT; HEALTH CARE QUALITY; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; INTERMETHOD COMPARISON; MANAGED CARE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR ACCESS; WELLBEING;

EUROPE; HEMODIAFILTRATION; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENAL REPLACEMENT THERAPY; TIME FACTORS; TOXINS, BIOLOGICAL; TREATMENT OUTCOME; UREMIA;

EID: 84864626995     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs184     Document Type: Review

References (66)

1. Port FK, Pisoni RL, Bommer J et al. Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2006; 1: 246-55.
2. Vanholder R, Glorieux G, Van Biessen W. Advantages of new hemodialysis membrane and equipment. Nephron Clin Pract 2010; 114: c165-c172.
3. Tetta C, Roy T, Gatti E et al. The rise of hemodialysis machines: new technologies in minimizing cardiovascular complications. Expert Rev Cardiovasc Ther 2011; 9: 155-164.
4. Rayner HC, Pisoni RL, Bommer J et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 108-120.
5. Goodkin DA, Young EW, Kurokawa K et al. Mortality among hemodialysis patients in Europe, Japan, and the United States: casemix effects. Am J Kidney Dis 2004; 44(5 Suppl 2): 16-21.
6. Foley RN, Hakim RM. Why is the mortality of dialysis patients in the United States much higher than the rest of the world? J Am Soc Nephrol 2009; 20: 1432-1435.
7. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277.
8. Canaud B, Wabel P, Tetta C. Dialysis prescription: a modifiable risk factor for chronic kidney disease patients. Blood Purif 2010; 29: 366-374.
9. Pan Y, Guo LL, Cai LL et al. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials. Br J Nutr 2012; 16: 1-8.
10. Meyer TW, Hostetter TH. Uremic solutes from colon microbes. Kidney Int 2012; 81: 949-954.
11. Goodkin DA, Pisoni RL, Locatelli F et al. Hemodialysis vascular access training and practices are key to improved access outcomes. Am J Kidney Dis 2010; 56: 1032-1042.
12. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med 2010; 363: 1833-1845.
13. Gotch FA. Evolution of the single-pool urea kinetic model. Semin Dial 2001; 14: 252-256.
14. Gotch F. The basic, quantifiable parameter of dialysis prescription is Kt/V urea; treatment time is determined by the ultrafiltration requirement; all three parameters are of equal importance. Blood Purif 2007; 25: 18-26.
15. Robert HB. Dialysis by the numbers: the false promise of Kt/V. Semin Dial 1989; 2: 207-212.
16. Eknoyan G, Beck GJ, Cheung AK et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
17. Cheung AK, Rocco MV, Yan G et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17: 546-555.
18. Locatelli F, Martin-Malo A, Hannedouche T et al. Membrane Permeability Outcome (MPO) Study Group. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-654.
19. Tattersall J, Martin-Malo A, Pedrini L et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant 2007; 22(Suppl. 2): ii5-ii21.
20. Spalding EM, Chamney PW, Farrington K. Phosphate kinetics during hemodialysis: evidence for biphasic regulation. Kidney Int 2002; 61: 655-667.
21. Ward RA, Greene T, Hartmann B et al. Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by postdilution hemodiafiltration. Kidney Int 2006; 69: 1431-1437.
22. Saran R, Bragg-Gresham JL, Levin NWet al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69: 1222-1228.
23. Culleton BF, Walsh M, Klarenbach SWet al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298: 1291-1299.
24. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009; 22: 636-643.
25. Marshall MR, Byrne BG, Kerr PG et al. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 2006; 69: 1229-1236.
26. Yashiro M, Kamata T, Segawa H et al. How does higher ultrafiltration within the conventional clinical range impact the volume status of hemodialysis patients? Blood Purif 2009; 27: 253-260.
27. Movilli E, Gaggia P, Zubani R et al. Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant 2007; 22: 3547-3552.
28. Vanholder R, De Smet R, Glorieux G et al. European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
29. Charra B, Chazot C, Laurent G et al. Clinical assessment of dry weight. Nephrol Dial Transplant 1996; 11(Suppl. 2): 16-19.
30. Rocco MV, Yan G, Heyka RJ et al. Hemo Study Group. Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 2001; 21: 280-288.
31. Wabel P, Moissl U, Chamney P et al. Towards improved cardiovascular management: the necessity of combining blood pressure and fluid overload. Nephrol Dial Transpl 2008; 23: 2965-2971.
32. Mark PB, Johnston N, Groenning BA et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006; 69: 1839-1845.
33. Ozkahya M, Ok E, Toz H et al. Long-term survival rates in haemodialysis patients treated with strict volume control. Nephrol Dial Transplant 2006; 21: 3506-3543.
34. Ifudu O. The concept of "dry weight" in maintenance hemodialysis: flaws in clinical application. Int J Artif Organs 1996; 19: 384-386.
35. Agarwal R, Alborzi P, Satyan S et al. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009; 53: 500-507.
36. Kooman JP, van der Sande FM, Leunissen KM. Role of sodium and volume in the pathogenesis of hypertension in dialysis patients. Reflections on pathophysiological mechanisms. Blood Purif 2004; 22: 55-59.
37. van Popele NM, Bos WJ, de Beer NA et al. Arterial stiffness as underlying mechanism of disagreement between an oscillometric blood pressure monitor and a sphygmomanometer. Hypertension 2000; 36: 484-488.
38. Chamney PW, Wabel P, Moissl UM et al. A whole-body model to distinguish excess fluid from the hydration of major body tissues. Am J Clin Nutr 2007; 85: 80-89.
39. Wizemann V, Wabel P, Chamney P et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 1574-1579.
40. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease- what have we learned in 10 years? Semin Dial 2010; 5: 498-509.
41. Ethier J, Mendelssohn DC, Elder SJ et al. Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2008; 23: 3219-3226.
42. Tordoir J, Canaud B, Haage P et al. EBPG on vascular access. Nephrol Dial Transplant 2007; 22(Suppl. 2): ii88-ii117.
43. Lopez-Vargas PA, Craig JC, Gallagher MP et al. Barriers to timely arteriovenous fistula creation: a study of providers and patients. Am J Kidney Dis 2011; 57: 873-882.
44. Zoccali C, Abramowicz D, Cannata-Andia JB et al. European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant 2008; 23: 2162-2166.
45. Vanholder R, Abramowicz D, Cannata-Andia JB et al. The future of European nephrology 'guidelines'-a declaration of intent by European Renal Best Practice (ERBP). Nephrol Dial Transplant Plus 2009; 2: 213-221.
46. López-Gómez JM, Pérez-Flores I, Jofré R et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15: 2494-2501.
47. Carracedo J, Merino A, Nogueras S et al. On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: a prospective, crossover study. J Am Soc Nephrol 2006; 17: 2315-2321.
48. McIntyre CW. Recurrent circulatory stress: the dark side of dialysis. Semin Dial 2010; 23: 449-451.
49. McIntyre CW, Harrison LE, Eldehni MT et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 133-141.
50. Schneider A, Drechsler C, Krane Vet al. Christoph Wanner, for the MINOXIS Study Investigators. The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: results of the MINOXIS Study. CJASN 2012; 7: 52-59.
51. Panichi V, Rosati A, Bigazzi R et al. on behalf of the RISCAVID Study Group. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26: 2641-2648.
52. Canaud B, Bragg-Gresham JL, Marshall MR et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69: 2087-2093.
53. Locatelli F, Altieri P, Andrulli S et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol 2010; 21: 1798-1807.
54. Pedrini LA, De Cristofaro V, Comelli M et al. Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multicentre prospective randomized study. Nephrol Dial Transplant 2011; 26: 2617-2624.
55. Blankestijn PJ, Ledebo I, Canaud B. Hemodiafiltration: clinical evidence and remaining questions. Kidney Int 2010; 77: 581-587.
56. Ok E, Asci G, Sevinc-Ok E et al. Comparison of postdilution online hemodiafiltration and hemodialysis (Turkish HDF study). ERAEDTA 2011; LBCT2.
57. Grooteman M, Van den Dorpel R, Bots M et al. Online hemodiafiltration versus low-flux hemodialysis: effects on all-cause mortality and cardiovascular events in a randomized controlled trial. The convective transport study (CONTRAST). J Am Soc Nephrol 2012 [Epub ahead of print April 26].
58. Locatelli F et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50: 1293-1302.
59. Locatelli F et al. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 1999; 55: 286-293.
60. Wizemann V et al. On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. NDT 2000; 15 Suppl 1: 43-48.
61. Bosch JP et al. Clinical use of high-efficiency hemodialysis treatments: long-term assessment. Hemodial Int 2006; 10: 73-81.
62. Jirka T et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis. Kidney Int 2006; 70: 1524; author reply 1524- 1525.
63. Schiffl H et al. Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysis. Eur J Med Res 2007; 12: 26-33.
64. Panichi V et al. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008; 23: 2337-2343.
65. Vilar E et al. Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol 2009; 4: 1944-1953.
66. Tiranathanagul K et al. On-line hemodiafiltration in Southeast Asia: a three-year prospective study of a single center. Ther Apher Dial 2009; 13: 56-62